Dizal Pharmaceutical(688192)2025-01-16 07:46Revenue Projections - The company expects to achieve approximately CNY 360 million in revenue for 2024, an increase of about CNY 268.71 million or 294.35% year-on-year[3]. - The company anticipates a revenue impact of approximately CNY 52 million due to price adjustments following the inclusion in the National Medical Insurance Drug List[5]. R&D Expenses and Progress - The estimated R&D expenses for 2024 are around CNY 738 million, a decrease of approximately CNY 67.60 million or 8.39% compared to the previous year[3]. - The company’s core product Shuwozhe® has received priority review from the FDA for a new drug application, indicating ongoing R&D progress[6]. - The company is actively conducting multiple clinical studies for its products, including DZD8586 and DZD6008, indicating a robust pipeline[6]. Net Loss Projections - The projected net loss attributable to the parent company for 2024 is approximately CNY 865 million, a reduction of about CNY 242.71 million or 21.91% year-on-year[3]. - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be around CNY 918 million, a decrease of approximately CNY 242.73 million or 20.91% year-on-year[3]. Product Approvals and Market Access - The company’s second core product, Gao Ruizhe®, received approval for market launch in June 2024, contributing to significant revenue growth[4]. - Both Shuwozhe® and Gao Ruizhe® have been included in the National Medical Insurance Drug List, effective January 1, 2025, enhancing their market accessibility[4]. Performance Forecast Accuracy - The company confirms that there are no significant uncertainties affecting the accuracy of this performance forecast[7].